AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get moving
Target
Upside 114%
Price (€) 4.53
Market Cap (€M) 164
Perf. 1W: 3.08%
Perf. 1M: 30.4%
Perf. 3M: 16.0%
Perf Ytd: 37.3%
10 day relative perf. to stoxx600: 7.09%
20 day relative perf. to stoxx600: 18.6%
EPS change26/09/2022

Minor changes after H1 22

Change in EPS2022 : € -0.32 vs -0.23ns
2023 : € -0.35 vs -0.25ns

We have only changed our short-term estimates after the release of the H1 22 results. These changes are minor and are limited to FY23-24) even if they look more significant in EPS terms due to the fact that the result is a small loss, implying that any change to our numbers translates into an apparent bigger change in percentage terms. The impact on our valuation of the stock is thus marginal.



Updates

26 Sep 22 EPS change
Minor changes after H1 22

23 Sep 22 Earnings/sales releases
A rather reassuring H1 22

29 Mar 22 Earnings/sales releases
FY21: not very meaningful, as expected

17 Dec 21 Financing issue
New financing

24 Sep 21 Earnings/sales releases
H1 21: unsurprising (as usual)

.